We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher
Read MoreHide Full Article
Translate Bio, Inc. (TBIO - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 42.6% in the past one-month time frame.
The upmove came following news that the company entered into a collaboration with Sanofi to develop a novel messenger RNA (mRNA) vaccine for COVID-19.
The company has seen a mixed track record when it comes to estimate revision of no increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Translate Bio currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher
Translate Bio, Inc. (TBIO - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 42.6% in the past one-month time frame.
The upmove came following news that the company entered into a collaboration with Sanofi to develop a novel messenger RNA (mRNA) vaccine for COVID-19.
The company has seen a mixed track record when it comes to estimate revision of no increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Translate Bio currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Translate Bio, Inc. Price
Translate Bio, Inc. price | Translate Bio, Inc. Quote
Investors interested in the Medical - Drugs industry may consider Cumberland Pharmaceuticals Inc. (CPIX - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>